Topically administered Risedronate shows powerful anti-osteoporosis effect in ovariectomized mouse model

Bone

Volumn 50, Issue 1, 2012, Pages 149-155

  Nam, So Hee ^a   Jeong, Jae Hwan ^b   Che, Xiangguo ^b   Lim, Kyung Eun ^b   Nam, Hyemi ^a   Park, Jong Sang ^a   Choi, Je Yong ^b  

^a Seoul National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

Osteoporosis; Ovariectomized mouse model; Risedronate; Topical delivery

Indexed keywords

ESTROGEN; MACROGOL; RISEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTI OSTEOPOROSIS EFFECT; ARTICLE; BONE DENSITY; BONE TURNOVER; BONE VOLUME; CELL COUNT; CELL SURFACE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; ESTROGEN DEFICIENCY; FEMALE; FEMUR; HISTOPATHOLOGY; MICRO-COMPUTED TOMOGRAPHY; MOUSE; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; OVARIECTOMY; PHENOTYPE; SHAM PROCEDURE; TIBIA; TRABECULAR BONE; TRABECULAR NUMBER; TRABECULAR SEPARATION; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; OSTEOPOROSIS; OVARIECTOMY; SKIN; TIBIA; X-RAY MICROTOMOGRAPHY;

EID: 80355125351     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.10.017     Document Type: Article

References (39)

1. Mortensen L., Charles P., Bekker P.J., Digennaro J., Johnston C.C. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998, 83:396.
2. Luckman S.P., Hughes D.E., Coxon F.P., Russell R.G.G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581-589.
3. Eastell R., Barton I., Hannon R., Chines A., Garnero P., Delmas P. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003, 18:1051-1056.
4. Thompson K., Rogers M. The molecular mechanisms of action of bisphosphonates. Clin Rev Bone Miner Metab 2007, 5:130-144.
5. Coxon F.P., Thompson K., Rogers M.J. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006, 6:307-312.
6. Kavanagh K.L., Guo K., Dunford J.E., Wu X., Knapp S., Ebetino F.H., et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Natl Acad Sci 2006.
7. Mitchell Heise, Pallone Clay, Nesbitt Russell, Melson The effect of dosing regimen on the pharmacokinetics of risedronate. Br J Clin Pharmacol 1999, 48:536-542.
8. Mitchell D.Y., Barr W.H., Eusebio R.A., Stevens K.A.P., Duke F.P., Russell D.A., et al. Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration. Pharm Res 2001, 18:166-170.
9. Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int 2010, 86:421-435.
10. Hamilton B., McCoy K., Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003, 14:259-262.
11. Reginster J.Y., Minne H., Sorensen O., Hooper M., Roux C., Brandi M., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000, 11:83-91.
12. Brooks J.K., Gilson A.J., Sindler A.J., Ashman S.G., Schwartz K.G., Nikitakis N.G. Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases. Oral Surg, Oral Med, Oral Pathol, Oral Radiol, Endodontol 2007, 103:780-786.
13. Ruggiero S.L., Mehrotra B., Rosenberg T.J., Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004, 62:527-534.
14. Novince C.M., Ward B.B., McCauley L.K. Osteonecrosis of the jaw: an update and review of recommendations. Cells Tissues Organs 2008, 189:275-283.
15. Choi J.-Y., Kim H.-J., Lee Y.-C., Cho B.-O., Seong H.-S., Cho M., et al. Inhibition of bone healing by pamidronate in calvarial bony defects. Oral Surg, Oral Med, Oral Pathol, Oral Radiol, Endodontol 2007, 103:321-328.
16. Prausnitz M.R., Langer R. Transdermal drug delivery. Nat Biotech 2008, 26:1261-1268.
17. Delivering drugs by the transdermal route: review and comment. Skin Res Technol 2008, 14:249-260.
18. Ramachandran C., Fleisher D. Transdermal delivery of drugs for the treatment of bone diseases. Adv Drug Deliv Rev 2000, 42:197-223.
19. Cramer J.A., Amonkar M.M., Hebborn A., Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis*. Curr Med Res Opin 2005, 21:1453-1460.
20. Boonen S., Orwoll E.S., Wenderoth D., Stoner K.J., Eusebio R., Delmas P.D. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 2009, 24:719-725.
21. Rossini M., Viapiana O., Gatti D., Adami S. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review. Clin Ther 2009, 31:1497-1510.
22. Emkey R., Delmas P.D., Bolognese M., Borges J.L.C., Cosman F., Ragi-Eis S., et al. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study. Clin Ther 2009, 31:751-761.
23. Recknor C. Zoledronic acid for prevention and treatment of osteoporosis. Expert Opin Pharmacother 2011, 12:807-815.
24. Mercier F., Lefevre G., Aaron Huang H.L., Schmidli H., Amzal B., Appel-Dingemanse S. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin 2007, 23:3199-3204.
25. Zhang S., Qin G., Wu Y., Gao Y., Qiu Y., Li F., et al. Enhanced bioavailability of l-carnitine after painless intradermal delivery vs. oral administration in rats. Pharm Res 2011, 28:117-123.
26. Matsumoto Y., Mikuni-Takagaki Y., Kozai Y., Miyagawa K., Naruse K., Wakao H., et al. Prior treatment with vitamin K2 significantly improves the efficacy of risedronate. Osteoporos Int 2009, 20:1863-1872.
27. Iwamoto J., Matsumoto H., Takeda T., Sato Y., Liu X., Yeh J.K. Effects of vitamin K 2 and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats. Calcif Tissue Int 2008, 83:121-128.
28. Choi A., Gang H., Whang J., Gwak H. Pharmacokinetic characteristics of formulated alendronate transdermal delivery systems in rats and humans. Drug Deliv 2010, 17:249-254.
29. Dohi M, Makino Y, Hujii T. Sodium alendronate preparation for local administration. In: Google Patents; 1999.
30. Graham R.G., Russell Z.X., Dunford James E., Udo Oppermann, Aarib Kwaasi, Hullley Philippa A., et al. Bisphosphonates. Ann N Y Acad Sci 2007, 1117:209-257.
31. Naik A., Kalia Y.N., Guy R.H. Transdermal drug delivery: overcoming the skin's barrier function. Pharm Sci Technol Today 2000, 3:318-326.
32. Banerjee S., Yalkowsky S.H., Valvani C. Water solubility and octanol/water partition coefficients of organics. Limitations of the solubility-partition coefficient correlation. Environ Sci Technol 1980, 14:1227-1229.
33. Barry B. Mode of action of penetration enhancers in human skin. J Control Release 1987, 6:85-97.
34. Dunn C.J., Goa K.L. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease. Drugs 2001, 61:685-712.
35. Halasy-Nagy J.M., Rodan G.A., Reszka A.A. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 2001, 29:553-559.
36. Teitelbaum S.L. Bone resorption by osteoclasts. Science 2000, 289:1504.
37. Robling A.G., Castillo A.B., Turner C.H. Biomechanical and molecular regulation of bone remodeling. Annu Rev Biomed Eng 2006, 8:455-498.
38. Sims N.A., Dupont S., Krust A., Clement-Lacroix P., Minet D., Resche-Rigon M., et al. Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-[beta] in bone remodeling in females but not in males. Bone 2002, 30:18-25.
39. Brinkmeier T., Kügler K., Lepoittevin J.-P., Frosch P.J. Adverse cutaneous drug reaction to alendronate. Contact Dermatitis 2007, 57:123-125.